|
EP3068396A1
|
|
Rapidly disintegrating formulations and methods of use
|
|
KR20160065970A
|
|
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
|
|
WO2015051259A1
|
|
Pharmaceutical compositions and methods of use
|
|
AU2014202306A1
|
|
Controlled release formulations of levodopa and uses thereof
|
|
WO2011090724A2
|
|
Gastroretentive solid oral dosage forms with lipid-based low-density excipient
|
|
WO2011090725A2
|
|
Gastroretentive solid oral dosage forms with swellable hydrophilic polymer
|
|
WO2010078429A1
|
|
Pharmaceutical dosage forms and methods of manufacturing same
|
|
WO2009100441A2
|
|
Depot formulations
|
|
AU2008343787A1
|
|
Controlled release formulations of levodopa and uses thereof
|
|
US2006057197A1
|
|
Pharmaceutical dosage forms having immediate release and/or controlled release properties
|
|
US2006013875A1
|
|
Combination immediate release controlled release levodopa/carbidopa dosage forms
|
|
US2005226927A1
|
|
Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
|
|
AU2005231433A1
|
|
Controlled release dosage for GABA receptor agonist
|
|
CN101001612A
|
|
Controlled release dosage for gaba receptor agonist
|
|
ZA200608190B
|
|
Controleld release dosage for GABA receptor antagonist
|
|
US2005147670A1
|
|
Oral disintegrating dosage forms
|
|
AU2003247409A1
|
|
Combination immediate release controlled release levodopa/carbidopa dosage forms
|
|
US7094427B2
|
|
Combination immediate release controlled release levodopa/carbidopa dosage forms
|
|
US6333332B1
|
|
Stabilized pharmaceutical compositions containing bupropion hydrochloride
|
|
US6531158B1
|
|
Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
|
